Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema

Young Hoon Kim, Joo Yoen Ko, Kee Chan Moon, Young Min Park, Young Joon Seo, Jae Hak Yoo, Kwanghoon Lee, Seung Chul Lee, Ai Young Lee, Seong Eon Kim, Ho Sun Jang, Choong Lim Haw, Young Suck Ro

Research output: Contribution to journalArticle

Abstract

Background: Fexofenadine (Allegra®) is a Hi-receptor selective antihistamine which exhibits consistent efficacy and safety in the treatment of allergic diseases. We thought that fexofenadine may be useful in treatment of the pruritus associated with eczema. Objective: The purpose of this study was to evaluate the efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Methods: In this study, patients with atopic and allergic contact dermatitis were divided into a group given fexofenadine 180 mg once daily with topical prednicarbate treatment group or a topical prednicarbate treatment only group, for 1 week. The primary efficacy parameter was the mean change from baseline in pruritus score, and the secondary parameters were the mean change in the incidence of scratching, the mean change in visual analogue scale (0-100 mm) of pruritus, and a comparison of patient satisfaction. Results: 435 patients were included and the mean age was 32.9 years old. The mean pruritus score at baseline was 3.55 point in fexofenadine group and 3.51 point in the control group. Regarding the mean change in pruritus score, fexofenadine significantly decreased the severity of pruritus compared with the control group (p<0.05). There were no significant differences in the decrease in the incidence of scratching between the two groups. A decrease in pruritus levels utilizing visual analogue scale was significant in the fexofenadine group (p<0.05) and patient satisfaction was significantly higher in the fexofenadine group (p=0.0192). There was no significant difference in the incidence of adverse events between two groups (p=0.6237). Conclusion: Fexofenadine administered 180 mg once daily in combination with topical prednicarbate treatment was effective and well tolerated in this study.

Original languageEnglish
Pages (from-to)151-159
Number of pages9
JournalKorean Journal of Dermatology
Volume46
Issue number2
Publication statusPublished - 2008 Feb 1

Fingerprint

fexofenadine
Eczema
Pruritus
Safety
Therapeutics
Visual Analog Scale
Patient Satisfaction
Incidence
Control Groups

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Kim, Y. H., Ko, J. Y., Moon, K. C., Park, Y. M., Seo, Y. J., Yoo, J. H., ... Ro, Y. S. (2008). Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Korean Journal of Dermatology, 46(2), 151-159.
Kim, Young Hoon ; Ko, Joo Yoen ; Moon, Kee Chan ; Park, Young Min ; Seo, Young Joon ; Yoo, Jae Hak ; Lee, Kwanghoon ; Lee, Seung Chul ; Lee, Ai Young ; Kim, Seong Eon ; Jang, Ho Sun ; Haw, Choong Lim ; Ro, Young Suck. / Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. In: Korean Journal of Dermatology. 2008 ; Vol. 46, No. 2. pp. 151-159.
@article{a7d11e5e3e00413a9beb27c255a5201e,
title = "Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema",
abstract = "Background: Fexofenadine (Allegra{\circledR}) is a Hi-receptor selective antihistamine which exhibits consistent efficacy and safety in the treatment of allergic diseases. We thought that fexofenadine may be useful in treatment of the pruritus associated with eczema. Objective: The purpose of this study was to evaluate the efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Methods: In this study, patients with atopic and allergic contact dermatitis were divided into a group given fexofenadine 180 mg once daily with topical prednicarbate treatment group or a topical prednicarbate treatment only group, for 1 week. The primary efficacy parameter was the mean change from baseline in pruritus score, and the secondary parameters were the mean change in the incidence of scratching, the mean change in visual analogue scale (0-100 mm) of pruritus, and a comparison of patient satisfaction. Results: 435 patients were included and the mean age was 32.9 years old. The mean pruritus score at baseline was 3.55 point in fexofenadine group and 3.51 point in the control group. Regarding the mean change in pruritus score, fexofenadine significantly decreased the severity of pruritus compared with the control group (p<0.05). There were no significant differences in the decrease in the incidence of scratching between the two groups. A decrease in pruritus levels utilizing visual analogue scale was significant in the fexofenadine group (p<0.05) and patient satisfaction was significantly higher in the fexofenadine group (p=0.0192). There was no significant difference in the incidence of adverse events between two groups (p=0.6237). Conclusion: Fexofenadine administered 180 mg once daily in combination with topical prednicarbate treatment was effective and well tolerated in this study.",
author = "Kim, {Young Hoon} and Ko, {Joo Yoen} and Moon, {Kee Chan} and Park, {Young Min} and Seo, {Young Joon} and Yoo, {Jae Hak} and Kwanghoon Lee and Lee, {Seung Chul} and Lee, {Ai Young} and Kim, {Seong Eon} and Jang, {Ho Sun} and Haw, {Choong Lim} and Ro, {Young Suck}",
year = "2008",
month = "2",
day = "1",
language = "English",
volume = "46",
pages = "151--159",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "2",

}

Kim, YH, Ko, JY, Moon, KC, Park, YM, Seo, YJ, Yoo, JH, Lee, K, Lee, SC, Lee, AY, Kim, SE, Jang, HS, Haw, CL & Ro, YS 2008, 'Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema', Korean Journal of Dermatology, vol. 46, no. 2, pp. 151-159.

Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. / Kim, Young Hoon; Ko, Joo Yoen; Moon, Kee Chan; Park, Young Min; Seo, Young Joon; Yoo, Jae Hak; Lee, Kwanghoon; Lee, Seung Chul; Lee, Ai Young; Kim, Seong Eon; Jang, Ho Sun; Haw, Choong Lim; Ro, Young Suck.

In: Korean Journal of Dermatology, Vol. 46, No. 2, 01.02.2008, p. 151-159.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema

AU - Kim, Young Hoon

AU - Ko, Joo Yoen

AU - Moon, Kee Chan

AU - Park, Young Min

AU - Seo, Young Joon

AU - Yoo, Jae Hak

AU - Lee, Kwanghoon

AU - Lee, Seung Chul

AU - Lee, Ai Young

AU - Kim, Seong Eon

AU - Jang, Ho Sun

AU - Haw, Choong Lim

AU - Ro, Young Suck

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: Fexofenadine (Allegra®) is a Hi-receptor selective antihistamine which exhibits consistent efficacy and safety in the treatment of allergic diseases. We thought that fexofenadine may be useful in treatment of the pruritus associated with eczema. Objective: The purpose of this study was to evaluate the efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Methods: In this study, patients with atopic and allergic contact dermatitis were divided into a group given fexofenadine 180 mg once daily with topical prednicarbate treatment group or a topical prednicarbate treatment only group, for 1 week. The primary efficacy parameter was the mean change from baseline in pruritus score, and the secondary parameters were the mean change in the incidence of scratching, the mean change in visual analogue scale (0-100 mm) of pruritus, and a comparison of patient satisfaction. Results: 435 patients were included and the mean age was 32.9 years old. The mean pruritus score at baseline was 3.55 point in fexofenadine group and 3.51 point in the control group. Regarding the mean change in pruritus score, fexofenadine significantly decreased the severity of pruritus compared with the control group (p<0.05). There were no significant differences in the decrease in the incidence of scratching between the two groups. A decrease in pruritus levels utilizing visual analogue scale was significant in the fexofenadine group (p<0.05) and patient satisfaction was significantly higher in the fexofenadine group (p=0.0192). There was no significant difference in the incidence of adverse events between two groups (p=0.6237). Conclusion: Fexofenadine administered 180 mg once daily in combination with topical prednicarbate treatment was effective and well tolerated in this study.

AB - Background: Fexofenadine (Allegra®) is a Hi-receptor selective antihistamine which exhibits consistent efficacy and safety in the treatment of allergic diseases. We thought that fexofenadine may be useful in treatment of the pruritus associated with eczema. Objective: The purpose of this study was to evaluate the efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Methods: In this study, patients with atopic and allergic contact dermatitis were divided into a group given fexofenadine 180 mg once daily with topical prednicarbate treatment group or a topical prednicarbate treatment only group, for 1 week. The primary efficacy parameter was the mean change from baseline in pruritus score, and the secondary parameters were the mean change in the incidence of scratching, the mean change in visual analogue scale (0-100 mm) of pruritus, and a comparison of patient satisfaction. Results: 435 patients were included and the mean age was 32.9 years old. The mean pruritus score at baseline was 3.55 point in fexofenadine group and 3.51 point in the control group. Regarding the mean change in pruritus score, fexofenadine significantly decreased the severity of pruritus compared with the control group (p<0.05). There were no significant differences in the decrease in the incidence of scratching between the two groups. A decrease in pruritus levels utilizing visual analogue scale was significant in the fexofenadine group (p<0.05) and patient satisfaction was significantly higher in the fexofenadine group (p=0.0192). There was no significant difference in the incidence of adverse events between two groups (p=0.6237). Conclusion: Fexofenadine administered 180 mg once daily in combination with topical prednicarbate treatment was effective and well tolerated in this study.

UR - http://www.scopus.com/inward/record.url?scp=41149108157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149108157&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:41149108157

VL - 46

SP - 151

EP - 159

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 2

ER -

Kim YH, Ko JY, Moon KC, Park YM, Seo YJ, Yoo JH et al. Efficacy and safety of fexofenadine in the treatment of pruritus associated with eczema. Korean Journal of Dermatology. 2008 Feb 1;46(2):151-159.